treatment related by the investigator, and no AESIs were reported. The setanaxib group had a 15% mean UPCR reduction at 24 weeks versus placebo. Two (15. 4%) setanaxib group patients had a UPCR reduction of 25% from baseline at 24 weeks, versus none in the placebo group. An ad hoc analysis showed that 5 (38. 5%) setanaxib group patients had a UPCR reduction of 10% versus baseline, compared with 1 (16. 7%) placebo group patient. The setanaxib group also had a 27% mean UPCR reduction at 4 weeks post dosing versus placebo. There was a 5% mean reduction in eGFR with setanaxib versus placebo at 24 weeks and a 4% reduction at 4 weeks post dosing. Conclusion: In patients with Alport syndrome, setanaxib plus background therapy had an acceptable safety profile with a trend towards UPCR reduction after 24 weeks of dosing and at 4 weeks post dosing versus background therapy alone.
García-Carro et al. (Wed,) studied this question.